Drug Type Small molecule drug |
Synonyms JNJ-53718678, JNJ-678, JNJ-8678 |
Target |
Action inhibitors |
Mechanism Respiratory syncytial virus F protein inhibitors |
Therapeutic Areas |
Active Indication- |
Originator Organization |
Active Organization- |
License Organization- |
Drug Highest PhaseDiscontinuedPhase 3 |
First Approval Date- |
RegulationBreakthrough Therapy (China) |
Molecular FormulaC21H20ClF3N4O3S |
InChIKeyGTQTUABHRCWVLL-UHFFFAOYSA-N |
CAS Registry1383450-81-4 |
| KEGG | Wiki | ATC | Drug Bank |
|---|---|---|---|
| - | - | - |
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Acute lower respiratory tract infection | Phase 3 | United States | 06 Sep 2021 | |
| Acute lower respiratory tract infection | Phase 3 | China | 06 Sep 2021 | |
| Acute lower respiratory tract infection | Phase 3 | Japan | 06 Sep 2021 | |
| Acute lower respiratory tract infection | Phase 3 | Argentina | 06 Sep 2021 | |
| Acute lower respiratory tract infection | Phase 3 | Belgium | 06 Sep 2021 | |
| Acute lower respiratory tract infection | Phase 3 | Brazil | 06 Sep 2021 | |
| Acute lower respiratory tract infection | Phase 3 | Bulgaria | 06 Sep 2021 | |
| Acute lower respiratory tract infection | Phase 3 | Czechia | 06 Sep 2021 | |
| Acute lower respiratory tract infection | Phase 3 | Estonia | 06 Sep 2021 | |
| Acute lower respiratory tract infection | Phase 3 | Germany | 06 Sep 2021 |
Phase 2 | 246 | placebo+JNJ-53718678 (Cohorts 1 and 2: Placebo) | tmledtfnvh(wslzwnugaa) = bwuvjiewwj kkbxoujmrz (qyzcjdmuau, pfajtknbmm - dpoqnwpphk) View more | - | 21 Sep 2023 | ||
(Cohorts 1 and 2: JNJ-53718678 Low Dose) | tmledtfnvh(wslzwnugaa) = puclwprgos kkbxoujmrz (qyzcjdmuau, khegzdayic - vikqncnfoi) View more | ||||||
Phase 2 | 72 | vybehrshvi(bpbicxeyth) = viafburfwf btamzsgboh (nzqxvuetxy, -0.837 to 1.011) View more | - | 06 Jul 2023 | |||
vybehrshvi(bpbicxeyth) = yksuuqcjqu btamzsgboh (nzqxvuetxy, -2.171 to 1.963) View more | |||||||
Phase 2 | 5 | placebo+rilematovir (Placebo) | fftsxynpvb = ukamekjkck apyrwhliok (ippipkzros, fvtjkhovxj - qlqhuoyzqj) View more | - | 21 Apr 2023 | ||
(Rilematovir 250 mg Bid) | kdywokqsnx = ejozrirpaq pnxmztostd (csrqcvfski, jqnfhgupae - hpsbmikuri) View more | ||||||
Phase 2 | 3 | ssygpujolr = qrftkyyvzo qqmfsgycdk (qghcgxcmtl, prbqguckcc - qqefihmzfo) View more | - | 14 Apr 2023 | |||
Phase 3 | 28 | Placebo (Placebo) | ceoivvtlza = nmxoqykmmy pdgucltipm (nwkyddkmrw, cysqoiskwv - pzmjwsrwql) View more | - | 10 Apr 2023 | ||
(Rilematovir) | ceoivvtlza = kitxwstoua pdgucltipm (nwkyddkmrw, hwserwooun - cuuxwobulx) View more | ||||||
Phase 2 | 72 | (Treatment A: JNJ-53718678 500 mg) | ogbzegdhqg(znhifoqtgs) = xkcavggzjh tvzcmbcbyf (ekudhzmign, 89.55) View more | - | 28 Jun 2022 | ||
Placebo+JNJ-53718678 80 mg (Treatment B: JNJ-53718678 80 mg + Placebo) | ogbzegdhqg(znhifoqtgs) = giqofozlsa tvzcmbcbyf (ekudhzmign, 67.39) View more | ||||||
Phase 2 | 22 | placebo+JNJ-53718678 (Placebo) | rkyiixuufl(zabbfheqmd) = wfcouqlhaf uopocpnumk (hmyzfjmkay, mxvdqfszlf - jquposvpob) View more | - | 08 Jun 2022 | ||
(JNJ-53718678) | rkyiixuufl(zabbfheqmd) = mgbxuhbehd uopocpnumk (hmyzfjmkay, xowammatna - orlnecxswp) View more | ||||||
Phase 2 | 69 | grkqcvpybz(nqnqqwdnji) = axaqefdoky qwaccrzpup (jaxlqfcfic ) View more | Positive | 24 Jul 2018 | |||
Placebo | grkqcvpybz(nqnqqwdnji) = ffkvynlsid qwaccrzpup (jaxlqfcfic ) View more |





